Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Test Type
1.1.2. End-use
1.1.3. Regional scope
1.1.4. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Test type outlook
2.2.2. End-use outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Tuberculosis Diagnostics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Tuberculosis Diagnostics Market Analysis Tools
3.4.1. Industry Analysis – Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
Chapter 4. Tuberculosis Diagnostics: Test Type Estimates & Trend Analysis
4.1. Tuberculosis Diagnostics Market: Key Takeaways
4.2. Tuberculosis Diagnostics Market: Movement & Market Share Analysis, 2022 & 2030
4.3. Radiographic Method
4.3.1. Radiographic method market estimates and forecasts, 2018 to 2030, (USD Million)
4.4. Diagnostic Laboratory Methods
4.4.1. Diagnostic laboratory methods market estimates and forecasts, 2018 to 2030, (USD Million)
4.5. Nucleic Acid Testing
4.5.1. Nucleic acid testing market estimates and forecasts, 2018 to 2030, (USD Million)
4.6. Phage Assay
4.6.1. Phage assay market estimates and forecasts, 2018 to 2030, (USD Million)
4.7. Detection of Latent Infection (Skin Test & IGRA)
4.7.1. Detection of latent infection market estimates and forecasts, 2018 to 2030, (USD Million)
4.8. Cytokine Detection Assay
4.8.1. Cytokine detection assay market estimates and forecasts, 2018 to 2030, (USD Million)
4.9. Detection of Drug Resistance (DST)
4.9.1. Detection of drug resistance (DST) market estimates and forecasts, 2018 to 2030, (USD Million)
4.10. Other Methods
4.10.1. Other methods market estimates and forecasts, 2018 to 2030, (USD Million)
Chapter 5. Tuberculosis Diagnostics: End-use Estimates & Trend Analysis
5.1. Tuberculosis Diagnostics Market: Key Takeaways
5.2. Tuberculosis Diagnostics Market: Movement & Market Share Analysis, 2022 & 2030
5.3. Diagnostic Laboratories
5.3.1. Diagnostic laboratories market estimates and forecasts, 2018 to 2030, (USD Million)
5.4. Hospitals & Clinics
5.4.1. Hospitals & clinics market estimates and forecasts, 2018 to 2030, (USD Million)
5.5. Others
5.5.1. Others market estimates and forecasts, 2018 to 2030, (USD Million)
Chapter 6. Tuberculosis Diagnostics Market: Regional Estimates & Trend Analysis
6.1. Regional Outlook
6.2. Tuberculosis Diagnostics Market by Region: Key Takeaways
6.3. North America
6.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.3.2. U.S.
6.3.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.3.3. Canada
6.3.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4. Europe
6.4.1. UK
6.4.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.2. Germany
6.4.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.3. France
6.4.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.4. Italy
6.4.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.5. Spain
6.4.5.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.6. Sweden
6.4.6.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.7. Norway
6.4.7.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.8. Denmark
6.4.8.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5. Asia Pacific
6.5.1. Japan
6.5.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.2. China
6.5.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.3. India
6.5.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.4. Australia
6.5.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.5. Thailand
6.5.5.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.6. South Korea
6.5.6.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.6. Latin America
6.6.1. Brazil
6.6.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.6.2. Mexico
6.6.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.6.3. Argentina
6.6.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.7. MEA
6.7.1. Saudi Arabia
6.7.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.7.2. South Africa
6.7.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.7.3. UAE
6.7.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.7.4. Kuwait
6.7.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Market Participant Categorization
7.2.1. Abbott Laboratories
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Product benchmarking
7.2.1.4. Strategic initiatives
7.2.2. Becton, Dickinson and Company
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. F. Hoffmann-La Roche AG
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Thermo Fisher Scientific Inc.
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. BioMérieux SA
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. Hain Lifescience GmbH
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. QIAGEN GmbH
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
7.2.8. Cepheid
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Product benchmarking
7.2.8.4. Strategic initiatives
7.2.9. Hologic, Inc.
7.2.9.1. Company overview
7.2.9.2. Financial performance
7.2.9.3. Product benchmarking
7.2.9.4. Strategic initiatives
7.2.10. BD
7.2.10.1. Company overview
7.2.10.2. Financial performance
7.2.10.3. Product benchmarking
7.2.10.4. Strategic initiatives
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/